Capsule Summaries From EASL

[Guest guest]

INDEPENDENT CONFERENCE COVERAGE

2011 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CLICK TO ACCESS

Conference Coverage From Berlin, Germany

CCO's Independent Conference Coverage of EASL 2011 in Berlin, Germany, includes

Capsule Summaries of the most clinically relevant data presented at the meeting,

an original CCO highlights slideset, and a CME-certified Expert Analysis.

To browse available coverage, click here or select a link below.

Capsule Summaries:

Capsule Summaries are “quick read” reviews of key oral and poster presentations,

handpicked by leading experts in hepatology. The comprehensive contents are

based on the actual data presented at the meeting—providing the most up-to-date

information.

CLICK TO ACCESS

From Podium to Practice: Clinical Impact of New Data From EASL 2011

Click a link below to access Capsule Summaries

REALIZE Subanalysis: IL28B Genotype Not Significantly Associated With SVR in

Treatment-Experienced Patients Receiving Telaprevir-Based Triple Therapy for HCV

Infection – Link

IL28B Genotype Predicts Lead-in Response, Likelihood of Shortened Therapy in

SPRINT-2 and RESPOND-2 Phase III Boceprevir Trials – Link

SILEN-C1: High Rate of Rapid and Sustained Virologic Response With Addition of

BI 201335 to Standard of Care for First-line Treatment of Genotype 1 HCV

Infection – Link

Ritonavir-Boosted Danoprevir Plus PegIFN/RBV Produces Potent Antiviral Activity

in Null Responders Infected With Genotype 1b HCV but High Rate of Viral

Breakthrough With Genotype 1a – Link

In Previous Null Responders With Genotype 1 HCV Infection, BMS-790052 Plus

BMS-650032 Produces SVR in 36% Receiving Dual Therapy, 100% Receiving

Concomitant PegIFN/RBV – Link

ZENITH Interim Results: Potent Antiviral Activity With 12 Weeks of VX-222 +

Telaprevir + PegIFN/RBV Quad Therapy, but Virologic Breakthrough Common With

VX-222 + Telaprevir Dual Therapy – Link

IL28B Genotype May Predict Response to PegIFN Treatment in Patients Chronically

Infected With HBeAg-Positive Hepatitis B – Link

Biochemical and Histopathologic Outcomes Not Improved With Addition of Metformin

or Losartan to Rosiglitazone vs Rosiglitazone Alone in Patients With NASH – Link

SOCRATES: Combining Sorafenib and TACE for Treatment of Advanced Hepatocellular

Carcinoma Yields Promising Efficacy Results – Link

This Conference Coverage is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Coming Soon: CME-Certified Expert Analysis

2011 Annual Meeting of the European Association for the Study of the Liver

Leading experts discuss the most clinically relevant data from the meeting in

Berlin, Germany, in a CME-certified Expert Analysis.

This program is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and

Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Pharmasset, Inc.; and

Vertex.

Clinical Care Options Hepatitis

GET MORE FROM CCO

2011 Annual CCO HIV and Hepatitis C Symposium

Register today for the 2011 Annual CCO HIV and Hepatitis C Symposium for a

review of the most important scientific and clinical advances over the past

year, including expert guidance on integrating novel HCV agents into clinical

care.

Click here for more information.

Conference Coverage

Journal Options

Management Series

Treatment Updates

Interactive Cases

Live Meetings

RSS / Podcasts

My CME Tracker

Free Bookstore

Slide Downloads

Copyright 2011 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

To ensure you receive Clinical Care Options educational materials by email,

please add info@... to your contacts or address book.

Not a member yet? Click here